Theralase Technologies (TSXV:TLT) Current Accrued Expense : C$0.43 Mil (As of Sep. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Current Accrued Expense?

Theralase Technologies's Current Accrued Expense for the quarter that ended in Sep. 2024 was C$0.43 Mil.

Theralase Technologies's quarterly Current Accrued Expense stayed the same from Mar. 2024 (C$0.24 Mil) to Jun. 2024 (C$0.24 Mil) but then increased from Jun. 2024 (C$0.24 Mil) to Sep. 2024 (C$0.43 Mil).

Theralase Technologies's annual Current Accrued Expense declined from Dec. 2021 (C$0.34 Mil) to Dec. 2022 (C$0.26 Mil) but then increased from Dec. 2022 (C$0.26 Mil) to Dec. 2023 (C$0.28 Mil).

Theralase Technologies Current Accrued Expense Historical Data

The historical data trend for Theralase Technologies's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Current Accrued Expense Chart

Theralase Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

0.95

0.36

0.34

0.26

0.28

Theralase Technologies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Current Accrued Expense	Get a 7-Day Free Trial															0.33	0.28	0.24	0.24	0.43

Theralase Technologies Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Theralase Technologies Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

TLTFF:USA TTX:Germany TTX:Germany

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.

Executives

Matthew Thomas Perraton	Director
Roger John Dumoulin-white	10% Security Holder, Director, Senior Officer
Kristina Maria Hachey	Senior Officer
Arkady Mandel	Senior Officer
Guy John Anderson	Director
Shawn Shirazi	Senior Officer